Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance

Zealand Pharma reported a smaller-than-expected first-quarter operating loss, helped by strong momentum in its obesity drug pipeline. The company also announced a share buyback of up to $200 million, signaling confidence in its outlook and adding a capital return catalyst. The update is constructive for the stock, though the move is likely to be company-specific rather than sector-wide.

Analysis

Zealand Pharma reported a smaller-than-expected first-quarter operating loss, helped by strong momentum in its obesity drug pipeline. The company also announced a share buyback of up to $200 million, signaling confidence in its outlook and adding a capital return catalyst. The update is constructive for the stock, though the move is likely to be company-specific rather than sector-wide.